SCHEMBL16201351

SCHEMBL16201351

CCCN(C)Cc1c[nH]nc1-c1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 2/20 0.42
RECQL P46063 1/20 0.42
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
ACHE P22303 4/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 2/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR1A P08908 2/20 0.34
HTR7 P34969 2/20 0.34
HSP90AA1 P07900 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201165 0.90 LMNA (0.44) LMNAKDM4ETDP1RECQLALDH1A1
SCHEMBL16201385 0.89 LMNA (0.38) LMNAKDM4ETDP1RECQLALDH1A1
SCHEMBL16201417 0.85 MEN1 (0.39) LMNAKDM4ETDP1ALDH1A1KMT2A
SCHEMBL16201356 0.85 ALDH1A1 (0.41) LMNAKDM4ETDP1RECQLALDH1A1
SCHEMBL16201381 0.84 CRHR1 (0.41) LMNAKDM4ETDP1KMT2AHTR2C
SCHEMBL16201406 0.84 TDP1 (0.34) LMNAKDM4ETDP1RECQLALDH1A1
SCHEMBL16201360 0.84 ALDH1A1 (0.36) LMNAKDM4ETDP1RECQLALDH1A1
SCHEMBL16201391 0.83 CHRM2 (0.45) ALDH1A1ACHESMN1; SMN2HTR2AHTR2C
SCHEMBL16201388 0.83 CFD (0.34) LMNAKDM4ETDP1RECQL
SCHEMBL16201399 0.83 SLC6A2 (0.35) LMNAKDM4ETDP1RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 LMNA 3763/4885KDM4E 157/4885TDP1 317/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 LMNA 4321/4885KDM4E 288/4885TDP1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.